RheumNow Podcast – The Beat Goes On (5.8.20) Save
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
- Anakinra works in CPPD. Metanalysis of biologics use finds 74 pts Rx with anakinra for refractory dz (85%) or w/ contraindications (23%). Anakinra resp seen in 81% of acute and 43% of chronic CPPD pts. Few adverse events reported (4.1%) https://bit.ly/2z8EB2T
- European Commission has approved Cosentyx (secukinumab) for Rx of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) based on results of the Phase III PREVENT trial. (NOT yet FDA/US approved for nr-axSpA) https://t.co/DAWWoG6MJP
- Cigarette Smoking and ANCA-Associated Vasculitis
- Case report of a stable GPA patient treated with pred and Rituxan on 3/5, developed COVID Sxs next day, progressed to high fever, resp failue, mech ventilaion, Rx with antivirals, HCQ; extubated day 20, negative PCR x2 and discharged day 29. https://t.co/SSSKRbYK2R
- World Scleroderma Found Recs on COVID 1) SSc w/ Lung dz may be at risk; 2) Cont Rx & avoid SSc lapse in Rx; 3) SSc pts dont need testing unless Sx+; 4) ACE/ARBs BP meds continued; 5) Initiating preventative Rx w/ HCQ is not recommended https://t.co/8BUE6tLLTi
- American Hospital Association (AHA), in a new report, projected a loss of $202.6 billion from COVID-19 expenses and lost revenue for US hospitals and health systems from Mar 1 to Jun 30—about $50 billion in losses each month. https://bit.ly/2YK0iRt
- Poor COVID outcomes related to active IBD, old age & comorbidities, but NOT to IBD treatments. 79 patients with IBD with COVID-19 were studied, 46% w/ pneumonia (46%), 28% hospitalised, 8% died, 6% adm with COVID-19 & a severe IBD flare. https://t.co/RKrsGlcWI5
- J Allergy Clinical immunology – Type I IFN immunoprofiling in COVID-19 pts. French study of 26 critically ill ICU COVID patients Rx/ w/ standard of care (no antiviral, immunotherapies), 14/26 req mech ventilation). Peak in IFN-α2 seen day 8-10 of Sxs, but 19% failed to produced IFN-I with poorer outcomes, longer ICU stays. https://t.co/hW6TZdjKBs
- COVID-19 and Thrombotic Complications
- Hydroxychloroquine and QTc Prolongation - 90 COVID hospitalized pts treated with HCQ (53 w/ azithromycin); 20% manifest QT > 500 msec on HCQ, more if on zpak or loop diurectis – close monitoring warranted
- Hydroxychloroquine's World of Confusion - What you Need to Know
- TNR – Grand Rounds I L-6 in Health & Disease, by Dr. Len Calabrese
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.